Lindberg was already CEO of the Stockholm-based biotech company from the relaunch of Oncopeptides in 2011 until June 2020. Then he became CSO and Duvall CEO.

The change in management follows the recent withdrawal of Pepaxo in the US. Oncopeptices has already taken steps to refocus and consolidate the company around research and development. In the first quarter of 2022, management will present a new strategy and plan for the future. Oncopeptides AB focuses on the research and development of therapies for difficult-to-treat haematological diseases.

“We are very pleased that Jakob will continue his dedicated engagement in Oncopeptides, and lead the refocus to a Sweden based R&D company. Jakob’s unique understanding of the platform technology and drug development will serve the company well for this phase and the journey ahead of us,” says Per-Wold Olsen, Chairman of Oncopeptides. “